Navigation Links
Quanterix Digital Immunoassay for Prostate Specific Antigen Improves Analytical Performance
Date:7/21/2011

CAMBRIDGE, Mass., July 21, 2011 /PRNewswire/ -- Quanterix Corporation, an in-vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA™, a fifth-generation digital immunoassay for Prostate Specific Antigen (PSA), demonstrated a robust 2-log improvement in sensitivity over today's ultrasensitive third-generation assays for measuring PSA in patients following radical prostatectomy.  The company's proprietary Single Molecule Array (SiMoA™) technology platform combines both digital and analog detection in one straightforward measurement, thereby broadening the range of protein detection that can be acquired from a small sample size.   Data will be presented at the American Association for Clinical Chemistry (AACC) 2011 Annual Meeting held July 24-28 in Atlanta, GA.  

"Because a radical prostatectomy removes the tissue responsible for producing PSA, measuring this protein in patients following surgery is very difficult with the assays available today," explains David Wilson Ph.D., Senior Director, Product Development at Quanterix and lead author of the study.  "The 1000-fold improvement in sensitivity from SiMoA enables us to accurately measure PSA levels in all post radical prostatectomy patients tested.   AccuPSA has the potential to provide precise and reliable measurements of a patients' PSA levels post surgery, which could enable risk stratification for cancer recurrence based on a single blood test.  This test could be a significant advance for physicians to determine the right treatment and monitoring plan going forward."

These data are part of a follow-up retrospective pilot study conducted by Quanterix that was designed to determine the ability of the test to predict 5-year biochemical recurrence-free survival following radical prostatectomy.  Data presented at the AACC will focus on the analytical performance of the AccuPSA test.  Clinical utility was also demonstrated and these results will be published later this year in a prominent peer-reviewed journal.

Poster Presentation Information:
Abstract # A-47
Analytical Performance of AccuPSA™, a Fifth-generation Digital Immunoassay for Prostate Specific Antigen
Session: 02/Cancer/Tumor Markers
Date/Time: 7/26/2011 10:00:00 AM

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cookstr Launches New Digital Recipe Collections Exclusively on Apples iBookstore
2. Brazilian Market for Dental Imaging Equipment 2011 (Digital Intraoral X-Ray Systems, Extraoral X-Ray Systems and CBCT Scanners)
3. Russian Market for Dental Imaging Equipment 2011 (Digital Intraoral X-Ray Systems, Extraoral X-Ray Systems and CBCT Scanners)
4. Chinese Market for Dental Imaging Equipment 2011 (Digital Intraoral X-Ray Systems, Extraoral X-Ray Systems and CBCT Scanners)
5. Digital Assent Secures $7.5 Million Series B Funding
6. Reportlinker Adds Advanced Digital Medical Equipment Products Market
7. Eveo Ranked #1 Independent Digital Healthcare Agency in U.S. 2nd Year in a Row
8. Roper Industries to Acquire Northern Digital, Inc.
9. City Medical, PC Adds Digital X-ray Machine
10. Digital Assent Signs 100th PatientPad® Customer
11. Varian Medical Systems to Exhibit the Latest Digital Image Detectors, X-Ray Tubes and Cancer Treatment Technologies at the CMEF Show in Shenzhen, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):